

COMMONWEALTH OF MASSACHUSETTS

SUFFOLK, ss

BOARD OF REGISTRATION
IN PHARMACY

In the Matter of)
Central Admixture) Docket No.: PHA-2024-0087
Pharmacy Services, Inc.)
NO00053)
Exp: 12/31/2025)

CONSENT AGREEMENT FOR REPRIMAND


The Massachusetts Board of Registration in Pharmacy (“Board”) and Central Admixture Pharmacy Services, Inc (“Facility or Licensee”), a Non-Resident Outsourcing Facility licensed by the Board, License Number NO00053, do hereby stipulate and agree that the following information shall be entered into and become a permanent part of the Licensee’s record maintained by the Board:

1. The Licensee acknowledges the Board opened a Complaint against its Massachusetts license related to the conduct set forth in Paragraph 2, identified as Docket Number PHA-2024-0087 (“Complaint”).
2. The Licensee and the Board agree to resolve the Complaint without making any admissions or findings and without proceeding to a formal adjudicatory hearing. The Complaint alleges the following:
 - a. The Licensee failed to notify the Board within 14 calendar days of an FDA inspection conducted at its location in Phoenix, AZ between June 21, 2023 to July 31, 2023 and the resultant issuance of a Form FDA 483 on July 31, 2023.
3. The Board and Licensee acknowledge and agree that based upon the information described in Paragraph 2 the Board could find the Licensee in violation of 247 CMR 21.09 (4) and (5), warranting disciplinary action by the Board under M.G.L. c. 112, §§ 42A & 61 and 247 CMR 21.06(4).
4. The Licensee agrees that the Board shall impose a REPRIMAND on its license based on the facts described in Paragraph 2, effective as of the date on which the Board signs this Agreement (“Effective Date”).
5. The Board agrees that in return for the Licensee’s execution and successful compliance with all the requirements of this Agreement, the Board will not prosecute the Complaint.
6. The Licensee understands that it has a right to a formal adjudicatory hearing concerning the Complaint and that during said adjudication the Licensee would possess the right to

Central Admixture Pharmacy Services, Inc.
NO00053
PHA-2024-0087

confront and cross-examine witnesses, to call witnesses, to present evidence, to testify on its own behalf, to contest the allegations, to present oral argument, to appeal to the courts, and all other rights as set forth in the Massachusetts Administrative Procedures Act, M.G.L. c. 30A, and the Standard Adjudicatory Rules of Practice and Procedure, 801 CMR 1.01 *et seq.* The Licensee further understands that by executing this Agreement the Licensee is knowingly and voluntarily waiving its right to a formal adjudication of the Complaints.


7. The Licensee acknowledges that it has been at all times represented by Counsel or otherwise free to seek and use legal counsel in connection with the Complaint and this Agreement.
8. The Licensee acknowledges that after the Effective Date, the Agreement constitutes a public record of disciplinary action by the Board subject to the Commonwealth of Massachusetts' Public Records Law, M.G.L. c. 4, § 7. The Board may forward a copy of this Agreement to other licensing boards, law enforcement entities, and other individuals or entities as required or permitted by law.
9. The Licensee understands and agrees that entering into this Agreement is a voluntary and final act and not subject to reconsideration, appeal or judicial review.
10. The individual signing this Agreement certifies that they are authorized to enter into this Agreement on behalf of the Licensee, and that they have read this Agreement.



Michael Godek, R.Ph
Executive Director
Board of Registration in Pharmacy

2025-08-14

Date



(signature)

Michael Galleno

(print name)
Michael Galleno
CVP & General Manager CAPS

2025-08-14

Date

Signed by:
Jim West
(signature)

Jim West
(print name)
Jim West
SVP & Chief Operations Officer

Effective Date of Reprimand Agreement 8/18/2025

Fully Signed Agreement Sent to Licensee on _____ by Certified Mail
No.

Central Admixture Pharmacy Services, Inc.
NO00053
PHA-2024-0087